Mar 28, 2017
OTC Disclosure & News Service
Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services
VALENCIA, SPAIN–(Marketwired – Mar 28, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that MIDS Medical Limited (“MML”), our joint venture based at Sci-Tech, Daresbury (UK), has engaged Future Diagnostics Solutions B.V. (“Future Diagnostics”) for assay development services.
Future Diagnostics is an independent, internationally oriented and certified service provider focused on the medical diagnostics and device industry based in Wijchen, the Netherlands.
Future Diagnostics is specialized in full IVD immunoassay development, biomarker qualification, point of care test development, and OEM contract manufacturing. Future Diagnostics offers flexible support in feasibility & optimization, verification, technical transfer, and validation. Its FDA-registered facility is fully compliant with all regulatory requirements to manufacture IVD products or assays going to market.
Future Diagnostics has developed assays for several of the world’s largest multi-national diagnostics companies and has recent experience in modern troponin assays. It also has expertise in additional areas key to MML, including paramagnetic particle based assays, POC and automated platform based technologies.
During the current testing and development phase MML will utilize Future Diagnostics’ consulting services to inform its development team of the MIDS design parameters regarding a future cardiac assay(s), planned to be embodied in a test strip in a second phase of development. This early access to Future Diagnostics’ expertise is expected to greatly assist MML in design areas such as microfluidic and magnetic detection optimization for MML’s planned high sensitivity troponin assay.
Dr. Nasser Djennati, Managing Director of MIDS Medical, commented: “Future Diagnostics is highly respected, efficient and a great fit for us. To have this knowledge base on tap will be very useful, both now and as we move into the next development phase.”
Dr. Ernst Lindhout, Research & Development Director at Future Diagnostics, commented: “The MIDS technology offers the prospect of high sensitivity magnetic detection in an automated, POC platform, a novel approach from current optical detection systems. We believe we can be of great assistance to help bring the high potential MIDS technology to market and are delighted to be working with MIDS Medical at this early stage.”
About Zenosense, Inc.
Zenosense Inc.’s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients.
To find out more about Zenosense (OTCQB: ZENO), visit our website at www.zenosense.com.
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed on filed on May 23, 2016, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.
Tel: +34 960 454 202